A Phase I Study of DCC-2618 in Patients with Advanced Glioma or Gastrointestinal Stromal Tumor (GIST)


Full Title

DCC-2618-01-001: A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies


Mutations in genes called KIT and PDGFRA can lead to cancer growth. DCC-2618 is an investigational drug designed to block signals from altered KIT and PDGFRA that cause cancers to grow. Laboratory studies and early clinical trials suggest that DCC-2618 may be able to slow or stop the growth of some cancer cells.

In this study, researchers are evaluating the safety and preliminary effectiveness of DCC-2618 in patients with high-grade glioma or gastrointestinal stromal tumor (GIST) that has continued to grow despite standard therapy. DCC-2618 is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have high-grade glioma or GIST that has continued to grow despite prior treatment and contains mutations in the KIT or PDGFRA genes.
  • At least 2 weeks must pass between the completion of previous therapies and entry into the study.
  • Patients must be able to do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Ping Chi at 646-888-4166.